TICKERNERD
Menu
KPRXKPRXHealthcare · Biotechnology

KPRX Stock Forecast: Kiora Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$2.76
+3.37% on the day

The 1 Wall Street analysts covering Kiora Pharmaceuticals, Inc. hold a median 12-month price target of $12 — +334.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$12.2M
Ticker Nerd rank
76 / 100
Median analyst target
$12
Analysts covering
1
Revenue$0.0
Operating income−$2.1M
Net income−$2.1M
Free cash flow−$1.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.2%
1M
+6.6%
YTD
+40.1%
1Y
+4.1%
From 52W high
−3.5%
From 52W low
+53.3%
$1.80
$2.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KPRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kiora Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
76 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Revisions
83
Accruals
79
Volatility
77
Growth
63
Momentum
62
Quality
52
Issuance
38
Value
10

Size (91): Smaller than most of the companies we track.

Value (10): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KPRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KPRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26KPRXHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $12Median $12High $12

The green dot is the last close — the median target sits +334.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy$10
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.ReiteratesBuy—
23 July 2024HC Wainwright & Co.MaintainsBuy—
20 May 2024HC Wainwright & Co.ReiteratesBuy—
27 Mar 2024HC Wainwright & Co.MaintainsBuy—
9 Feb 2024HC Wainwright & Co.MaintainsBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
6 Nov 2023HC Wainwright & Co.MaintainsBuy—
24 Aug 2023HC Wainwright & Co.ReiteratesBuy—
14 Aug 2023HC Wainwright & Co.MaintainsBuy—
9 Aug 2023Maxim GroupMaintainsBuy—
12 May 2023HC Wainwright & Co.MaintainsBuy—
24 Mar 2023HC Wainwright & Co.ReiteratesBuy—
9 Feb 2023Maxim GroupUpgradeBuy—
8 Feb 2023HC Wainwright & Co.ReiteratesBuy—
8 Feb 2023Ladenburg ThalmannReiteratesBuy—
25 Aug 2022Ladenburg ThalmannInitiatesBuy$6.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KPRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KPRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Kiora Pharmaceuticals, Inc. returned +4.1% against +16.3% for the S&P 500, dividends included.

KPRX vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26KPRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KPRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Kiora Pharmaceuticals, Inc. (KPRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.7×

Cheaper than 67% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−56.4%

Higher than 20% of US stocks

Return on assets
−21.9%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kiora Pharmaceuticals, Inc. (KPRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kiora Pharmaceuticals, Inc. has a market value of $12.2M and an enterprise value of $1.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$11.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.6M.

  • Shares outstanding: 4.4M.

  • Trailing P/E: 3.7×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kiora Pharmaceuticals, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

KPRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KPRXKiora Pharmaceuticals, Inc.$12.2M
76
AEONAEON Biopharma, Inc.$12.1M
50
NRSNNeurosense Therapeutics Ltd.$12.0M
3
PHIOPhio Pharmaceuticals Corp.$12.0M
16
ADILAdial Pharmaceuticals, Inc.$12.8M
21
GDTCCytoMed Therapeutics Ltd.$11.6M
18
GTBPGT Biopharma, Inc.$12.9M
16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kiora Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KPRX news & analysis

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Newsfile Corp · 19 Aug 2026positive

Kiora Pharmaceuticals announced it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation, a leading South Korean pharmaceutical company based in Seoul.

Why it matters — This expands the potential development and commercialization reach of Kiora's KIO-301 by partnering with an established pharmaceutical company in the South Korean market.

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Newsfile Corp · 7 Aug 2026positive

Kiora Pharmaceuticals reported its second-quarter 2026 financial results, highlighting advanced enrollment into the higher-dose cohort of the Phase 2 ABACUS-2 trial of KIO-301 and continued enrollment in the higher-dose cohort of the Phase 2 KLARITY trial of KIO-104. The company ended the quarter with about $16.8 million in cash and short-term investments, providing an expected operating runway into late 2028, and secured a private placement of up to $24.0 million in gross proceeds.

Why it matters — This update shows pipeline progress in both Phase 2 trials and a funding runway into late 2028, giving KPRX watchers a view of the company's clinical and financial position.

FAQ

Frequently asked questions about KPRX stock

What is the KPRX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Kiora Pharmaceuticals, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KPRX stock a buy right now?

Of the 1 analysts covering Kiora Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kiora Pharmaceuticals, Inc. 76 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KPRX?

As at 19 Sept 2026, Kiora Pharmaceuticals, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will KPRX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +334.8% from the last close, and Ticker Nerd's factor model ranks Kiora Pharmaceuticals, Inc. 76 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KPRX stock forecast for 2030?

No analyst covering Kiora Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has KPRX stock performed over the past year?

Kiora Pharmaceuticals, Inc. returned +4.1% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kiora Pharmaceuticals, Inc. do?

Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other ophthalmic diseases.

What is the latest news on KPRX?

The most recent item we track (Newsfile Corp, 19 Aug 2026): "Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation". Kiora Pharmaceuticals announced it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation, a leading South Korean pharmaceutical company based in Seoul.

Company

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other ophthalmic diseases. The company uses innovative small molecules to target pathways involved in vision loss, with programs designed to preserve, slow, or restore visual function. Its pipeline includes therapies under development for inherited retinal disorders, inflammatory eye conditions, and corneal repair applications, reflecting a specialization in diseases with limited treatment options. Kiora Pharmaceuticals Inc. works at the intersection of eye health and drug development, addressing both rare and more broadly relevant ophthalmic indications through its research and clinical programs. Headquartered in Encinitas, California, the company plays a niche role in the healthcare sector by advancing experimental therapies aimed at unmet needs in vision care.

CEO Dr. Brian M. Strem Ph.D. · 13 employees · United States · https://www.kiorapharma.com